Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy

References

• Morgan E, Arnold M, Gini A, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut [Internet]. 2023 [cited 2023 Nov 27];72(2):338–344. doi: 10.1136/gutjnl-2022-327736
   Google Scholar
• Garborg K, Holme Ø, Løberg M, et al. Current status of screening for colorectal cancer. Ann Oncol [Internet]. 2013 [cited 2023 Nov 27];24(8):1963–1972. Available from: https://pubmed.ncbi.nlm.nih.gov/23619033/
   PubMed Web of Science ®Google Scholar
• Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol [Internet]. 2009 [cited 2023 Nov 27];27(6):872–877. doi: 10.1200/JCO.2008.19.5362
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin [Internet]. 2022 [cited 2023 Nov 27];72(1):7–33. doi: 10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Nordlinger B, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol [Internet]. 2014 [cited 2023 Nov 28];25(Suppl 3):iii1–iii9. Available from: https://pubmed.ncbi.nlm.nih.gov/25190710/
   PubMed Web of Science ®Google Scholar
• Saltz LB, Douillard J-Y, Pirotta N, et al. Irinotecan plus Fluorouracil/Leucovorin for metastatic colorectal cancer: a new survival standard. Oncology. 2001;6(1):81–91. doi: 10.1634/theoncologist.6-1-81
   Google Scholar
• de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol [Internet]. 2000 [cited 2023 Nov 28];18(16):2938–2947. doi: 10.1200/JCO.2000.18.16.2938
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol [Internet]. 2008 [cited 2023 Nov 28];26(12):2013–2019. doi: 10.1200/JCO.2007.14.9930
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med [Internet]. 2004 [cited 2023 Nov 28];350(23):2335–2342. doi: 10.1056/NEJMoa032691
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Köhne CH, Ciardiello F, et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J cancer [Internet]. 2015 [cited 2023 Nov 28];51(10):1243–1252. doi: 10.1016/j.ejca.2015.04.007
   PubMed Web of Science ®Google Scholar
• Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol [Internet]. 2014 [cited 2023 Nov 29];25(7):1346–1355. doi: 10.1093/annonc/mdu141
   PubMed Web of Science ®Google Scholar
• Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti–epidermal growth factor receptor antibody therapies. Cancer Research. 2007 [cited 2023 Nov 30];67(6):2643–2648. Available from: https://pubmed.ncbi.nlm.nih.gov/17363584/
   PubMed Web of Science ®Google Scholar
• Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer [Internet]. 2019 [cited 2021 Aug 23];381:p. 1632–1643. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa1908075
   Google Scholar
• André T, Shiu K-K, Kim TW, et al. Pembrolizumab in microsatellite-Instability–High advanced colorectal cancer. N Engl J Med [Internet]. 2020 [cited 2023 Sep 21];383(23):2207–2218. Available from: https://pubmed.ncbi.nlm.nih.gov/33264544/
   PubMed Web of Science ®Google Scholar
• Adeleke S, Haslam A, Choy A, et al. Microsatellite instability testing in colorectal patients with lynch syndrome: lessons learned from a case report and how to avoid such pitfalls. Per Med [Internet]. 2022 [cited 2024 Apr 15];19(4):277–286. doi: 10.2217/pme-2021-0128
   PubMedGoogle Scholar
• Hong DS, Fakih MG, Strickler JH, et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N Engl J Med [Internet]. 2020 [cited 2023 May 24];383(13):1207–1217. doi: 10.1056/NEJMoa1917239
   PubMed Web of Science ®Google Scholar
• Weiss J, Yaegar RD, Johnson ML, et al. KRYSTAL-1: adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation. Ann Oncol. 2021; European S. 32:S1294. doi: 10.1016/j.annonc.2021.08.2093
   PubMed Web of Science ®Google Scholar
• Klempner SJ, Weiss J, Pelster M, et al. LBA24 KRYSTAL-1: updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation. Ann Oncol [Internet]. 2022 [cited 2023 May 24];33:S1391. Available from: http://www.annalsofoncology.org/article/S0923753422038984/fulltext
   Web of Science ®Google Scholar
• Weiss J, Yaeger RD, Johnson ML, et al. COLORECTAL CANCER LBA6 KRYSTAL-1: adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (pts) with colorectal cancer (CRC) harboring a KRASG12C mutation. Ann Oncol [Internet]. 2021 [cited 2022 Feb 3];32:S1294. doi: 10.1016/j.annonc.2021.08.2093
   PubMed Web of Science ®Google Scholar
• Porębska I, Harłozińska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumor Biol. 2000 [cited 2023 Nov 28];21(2):105–115. Available from: https://pubmed.ncbi.nlm.nih.gov/10686540/
   PubMed Web of Science ®Google Scholar
• Gamboa-Dominguez A, Dominguez-Fonseca C, Quintanilla-Martinez L, et al. Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system. Mod Pathol. 2004;17(5):579–587. doi: 10.1038/modpathol.3800085
   PubMed Web of Science ®Google Scholar
• Pinkas-Kramarski R, Alroy I, Yarden Y. ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling. J Mammary Gland Biol Neoplasia. 1997;2(2):97–107. doi: 10.1023/A:1026343528967
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med [Internet]. 2008 [cited 2023 Nov 30];358(11):1160–1174. doi: 10.1056/NEJMra0707704
   PubMed Web of Science ®Google Scholar
• Misale S, Di Nicolantonio F, Sartore-Bianchi A, et al. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov Internet]. 2014 [cited 2023 Nov 30];4(11):1269–1280. doi: 10.1158/2159-8290.CD-14-0462
   PubMed Web of Science ®Google Scholar
• Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol [Internet]. 2008 [cited 2023 Nov 30];9(10):962–972. doi: 10.1016/S1470-2045(08)70206-7
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). 2013 [cited 2023 Nov 28]. Available from: www.ema.europa.eu
   Google Scholar
• Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol [Internet]. 2017 [cited 2023 Aug 9];28:1713. Available from: /pmc/articles/PMC6246616/
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Lenz HJ, Köhne CH, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol [Internet]. 2015 [cited 2023 Nov 28];33(7):692–700. doi: 10.1200/JCO.2014.59.4812
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol [Internet]. 2011 [cited 2023 Nov 28];29(15):2011–2019. doi: 10.1200/JCO.2010.33.5091
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol [Internet]. 2011 [cited 2023 Nov 28];22(7):1535–1546. doi: 10.1093/annonc/mdq632
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol [Internet]. 2009 [cited 2023 Nov 28];27(5):663–671. doi: 10.1200/JCO.2008.20.8397
   PubMed Web of Science ®Google Scholar
• Yaeger R, Weiss J, Pelster MS, et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med [Internet]. 2023 [cited 2023 Dec 4];388(1):44–54. doi: 10.1056/NEJMoa2212419
   PubMed Web of Science ®Google Scholar
• Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, Binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer. N Engl J Med [Internet]. 2019 [cited 2023 Dec 4];381(17):1632–1643. doi: 10.1056/NEJMoa1908075:
   PubMed Web of Science ®Google Scholar
• Richman SD, Southward K, Chambers P, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol [Internet]. 2016 [cited 2023 Nov 30];238(4):562–570. doi: 10.1002/path.4679
   PubMed Web of Science ®Google Scholar
• Hyman DM, Blay J-Y, Chau I, et al. VE-BASKET, a first-in-kind, phase II, histology-independent “basket” study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m);32:2533–2533. doi: 10.1200/jco20143215_suppl2533.2014
   Google Scholar
• Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature [Internet]. 2012 [cited 2023 Aug 9];483(7387):100–103. Available from: https://pubmed.ncbi.nlm.nih.gov/22281684/
   Google Scholar
• Amodio V, Yaeger R, Arcella P, et al. EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer analysis and interpretation of data: HHS public access. Cancer Discov. 2020;10(8):1129–1139. doi: 10.1158/2159-8290.CD-20-0187
   PubMed Web of Science ®Google Scholar
• Saridaki Z, Tzardi M, Sfakianaki M, et al. BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients’ outcome. PLOS ONE. 2013 [cited 2023 May 9];8:e84604. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0084604
   PubMed Web of Science ®Google Scholar
• Tabernero J, Ros J, E É. The evolving treatment landscape in BRAF-V600E-Mutated metastatic colorectal cancer. Am Soc Clin Oncol Educ Book [Internet]. 2022 [cited 2023 May 9];42:254–263. Available from: https://pubmed.ncbi.nlm.nih.gov/35503983/
   Google Scholar
• Venderbosch S, Nagtegaal ID, Maughan TS, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res [Internet]. 2014 [cited 2023 May 9];20(20):5322–5330. doi: 10.1158/1078-0432.CCR-14-0332
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499–3506. doi: 10.1200/JCO.2012.42.8201
   PubMed Web of Science ®Google Scholar
• Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16(5):499–508. doi: 10.1016/S1470-2045(15)70127-0
   PubMed Web of Science ®Google Scholar
• Cremolini C, Antoniotti C, Stein A, et al. Individual Patient Data Meta-Analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J Clin Oncol. 2020;38(28):3314–3324. doi: 10.1200/JCO.20.01225
   Web of Science ®Google Scholar
• Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up 5 behalf of the ESMO Guidelines Committee. Ann Oncol. 2023 [cited 2023 Mar 3];34(1):10–32. doi: 10.1016/j.annonc.2022.10.003
   PubMed Web of Science ®Google Scholar
• Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med [Internet]. 2015 [cited 2022 Feb 1];373(8):726–736. doi: 10.1056/NEJMoa1502309
   PubMed Web of Science ®Google Scholar
• Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012 [cited 2023 May 9];379(9829):1893–1901. Available from: https://pubmed.ncbi.nlm.nih.gov/22608338/
   PubMed Web of Science ®Google Scholar
• Corcoran RB, Ebi H, Turke AB, et al. EGFR-Mediated reactivation of MAPK signaling contributes to insensitivity of BRAF -mutant colorectal cancers to RAF inhibition with Vemurafenib. Cancer Discovery. 2012 [cited 2022 Feb 1];2(3):227–235. Available from: https://pubmed.ncbi.nlm.nih.gov/22448344/
   PubMed Web of Science ®Google Scholar
• Corcoran RB, Andre T, Atreya CE, et al. Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-Mutant colorectal cancer. Cancer Discov [Internet]. 2018 [cited 2022 Feb 8];8(4):428–443. doi: 10.1158/2159-8290.CD-17-1226
   PubMed Web of Science ®Google Scholar
• Tabernero J, Geel RV, Guren TK, et al. Phase 2 results: encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC). J Clin Oncol. 2016;34(15_suppl):3544–3544. doi: 10.1200/JCO.2016.34.15_suppl.3544
   PubMed Web of Science ®Google Scholar
• Kopetz S, Guthrie KA, Morris VK, et al. Randomized Trial of Irinotecan and cetuximab with or without vemurafenib in BRAF-Mutant metastatic colorectal cancer (SWOG S1406). J Clin Oncol [Internet]. 2021 [cited 2022 Feb 9];39(4):285–294. doi: 10.1200/JCO.20.01994
   PubMed Web of Science ®Google Scholar
• Ros J, Matito J, Villacampa G, et al. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. Ann Oncol. 2023 [cited 2023 Aug 17];34(6):543–552. doi: 10.1016/j.annonc.2023.02.016
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Taieb J, Yaeger R, et al. ANCHOR CRC: results from a single-arm, phase II study of encorafenib plus binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic colorectal cancer. J Clin Oncol. 2023 [cited 2023 May 24];41(14):2628–2637. Available from: http://www.ncbi.nlm.nih.gov/pubmed/36763936
   PubMed Web of Science ®Google Scholar
• Kopetz S, Yoshino T, Kim TW, et al. BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAF V600E metastatic colorectal cancer (mCRC). J Clin Oncol [Internet]. 2023 [cited 2023 Aug 17];41(4_suppl):119–119. doi 10.1200/JCO.2023.41.4_suppl.119
   Google Scholar
• Conlin A, Smith G, Carey FA, et al. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut [Internet]. 2005 [cited 2023 Oct 9];54(9):1283–1286. Available from: https://pubmed.ncbi.nlm.nih.gov/15843421/
   Google Scholar
• Yokota T. Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anticancer Agents Med Chem [Internet]. 2012 [cited 2023 May 16];12(2):163. Available from: /pmc/articles/PMC3343383/
   PubMed Web of Science ®Google Scholar
• Schirripa M, Cremolini C, Loupakis F, et al. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int J Cancer [Internet]. 2015 [cited 2023 May 16];136(1):83–90. doi: 10.1002/ijc.28955:
   PubMed Web of Science ®Google Scholar
• Hong DS, Fakih MG, Strickler JH, et al. KRAS G12C inhibition with sotorasib in advanced solid tumors. N Engl J Med [Internet]. 2020 [cited 2022 Feb 3];383(13):1207–1217. doi: 10.1056/NEJMoa1917239
   PubMed Web of Science ®Google Scholar
• Amodio V, Yaeger R, Arcella P, et al. EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer. Cancer discov [Internet]. 2020 [cited 2023 May 17];10(8):1129–1139. doi: 10.1158/2159-8290.CD-20-0187
   PubMed Web of Science ®Google Scholar
• Fakih MG, Salvatore L, Esaki T, et al. Sotorasib plus Panitumumab in refractory colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023;389(23):2125–2139. doi: 10.1056/NEJMoa2308795
   PubMed Web of Science ®Google Scholar
• Siravegna G, Mussolin B, Buscarino M, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med [Internet]. 2015 [cited 2023 May 17];21(7):795–801. Available from: https://www.nature.com/articles/nm.3870
   PubMed Web of Science ®Google Scholar
• Mauri G, Pizzutilo EG, Amatu A, et al. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies. Cancer Treat Rev [Internet]. 2019 [cited 2023 May 23];73:41–53. doi: 10.1016/j.ctrv.2018.12.006
   PubMed Web of Science ®Google Scholar
• Martinelli E, Martini G, Famiglietti V, et al. Cetuximab Rechallenge Plus Avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial. JAMA Oncol [Internet]. 2021 [cited 2023 Aug 22];7(10):1529–1535. doi: 10.1001/jamaoncol.2021.2915
   PubMed Web of Science ®Google Scholar
• Cremolini C, Rossini D, Dell’aquila E, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to First-line Cetuximab and Irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol [Internet]. 2019 [cited 2024 Jan 8];5(3):343–350. doi: 10.1001/jamaoncol.2018.5080
   PubMed Web of Science ®Google Scholar
• Sunakawa Y, Nakamura M, Ishizaki M, et al. RAS mutations in circulating tumor DNA and clinical outcomes of rechallenge treatment with anti-EGFR antibodies in patients with metastatic colorectal cancer. JCO Precis Oncol [Internet]. 2020 [cited 2024 Jan 8];4(4):898–911. doi: 10.1200/PO.20.00109
   PubMedGoogle Scholar
• Cremolini C, Rossini D, Dell’aquila E, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to First-line Cetuximab and Irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol [Internet]. 2019 [cited 2023 May 23];5:343. Available from: /pmc/articles/PMC6439839/
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Pietrantonio F, Lonardi S, et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med [Internet]. 2022 [cited 2023 May 23];28(8):1612–1618. doi: 10.1038/s41591-022-01886-0
   PubMed Web of Science ®Google Scholar
• Alese OB, Wu C, Chapin WJ, et al. Update on emerging therapies for advanced colorectal cancer. Am Soc Clin Oncol Educ Book [Internet]. 2023 [cited 2023 Dec 1];43(43):e389574. Available from: http://www.ncbi.nlm.nih.gov/pubmed/37155942
   PubMedGoogle Scholar
• Zhao B, Wang L, Qiu H, et al. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget [Internet]. 2017 [cited 2023 Nov 30];8(3):3980–4000. doi: 10.18632/oncotarget.14012
   PubMedGoogle Scholar
• Benson AB, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw [Internet]. 2022 [cited 2023 Dec 1];20(10):1139–1167. Available from: https://pubmed.ncbi.nlm.nih.gov/36240850/
   PubMedGoogle Scholar
• Raghav K, Loree JM, Morris JS, et al. Validation of HER2 amplification as a predictive biomarker for anti–epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. JCO Precision Oncology. 2019 [cited 2023 Nov 30];3(3):1–13. Available from: https://pubmed.ncbi.nlm.nih.gov/35100667/
   PubMedGoogle Scholar
• Jeong JH, Kim J, Hong YS, et al. HER2 amplification and cetuximab efficacy in patients with metastatic colorectal cancer harboring wild-type RAS and BRAF. Clin Colorectal Cancer [Internet]. 2017 [cited 2023 Nov 30];16(3):e147–e152. doi: 10.1016/j.clcc.2017.01.005
   PubMed Web of Science ®Google Scholar
• Yonesaka K, Zejnullahu K, Okamoto I, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med [Internet]. 2011 [cited 2023 Dec 1];399. doi: 10.1126/scitranslmed.3002442
   PubMed Web of Science ®Google Scholar
• Mohan S, Heitzer E, Ulz P, et al. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLOS Genet [Internet]. 2014 [cited 2023 Dec 1];10(3):e1004271. doi: 10.1371/journal.pgen.1004271
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol [Internet]. 2019 [cited 2023 Dec 1];20(4):518–530. doi: 10.1016/S1470-2045(18)30904-5
   PubMed Web of Science ®Google Scholar
• Gupta R, Meric-Bernstam F, Rothe M, et al. Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2/3 mutations: results from the TAPUR study. JCO Precis Oncol [Internet]. 2022 [cited 2023 Dec 1];6(6). doi: 10.1200/PO.22.00306
   Google Scholar
• Nakamura Y, Okamoto W, Kato T, et al. Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nat Med [Internet]. 2021 [cited 2023 Dec 1];27(11):1899–1903. doi: 10.1038/s41591-021-01553-w
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol [Internet]. 2016 [cited 2023 Dec 1];17(6):738–746. doi: 10.1016/S1470-2045(16)00150-9
   PubMed Web of Science ®Google Scholar
• Fu X, Ying J, Yang L, et al. Dual targeted therapy with pyrotinib and trastuzumab for HER2 -positive advanced colorectal cancer: a phase 2 trial. Cancer Sci [Internet]. 2023 [cited 2023 Dec 1];114(3):1067. Available from: /pmc/articles/PMC9986078/
   PubMed Web of Science ®Google Scholar
• Strickler JH, Zemla T, Ou F-S, et al. Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): initial results from the MOUNTAINEER trial. Ann Oncol [Internet]. 2019 [cited 2023 Dec 1];30(v200. Available from: http://www.annalsofoncology.org/article/S0923753419587488/fulltext
   PubMedGoogle Scholar
• Sartore-Bianchi A, Lonardi S, Martino C, et al. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. ESMO Open [Internet]. 2020 [cited 2023 Dec 3];5. Available from 5):e000911. doi: 10.1136/esmoopen-2020-000911
   PubMed Web of Science ®Google Scholar
• Siena S, Raghav K, Masuishi T, et al. 386O exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC). Ann Oncol [Internet]. 2021 [cited 2023 Dec 3];32:S532. Available from: http://www.annalsofoncology.org/article/S0923753421031379/fulltext
   Web of Science ®Google Scholar
• Leto SM, Sassi F, Catalano I, et al. Sustained inhibition of HER3 and EGFR is necessary to induce regression of HER2-amplified gastrointestinal carcinomas. Clin Cancer Res [Internet]. 2015 [cited 2023 Dec 1];21(24):5519–5531. doi: 10.1158/1078-0432.CCR-14-3066
   PubMed Web of Science ®Google Scholar
• Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov [Internet]. 2011 [cited 2023 Dec 1];1(6):508–523. doi: 10.1158/2159-8290.CD-11-0109
   PubMed Web of Science ®Google Scholar
• Valtorta E, Martino C, Sartore-Bianchi A, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol [Internet]. 2015 [cited 2023 Dec 1];28(11):1481–1491. doi: 10.1038/modpathol.2015.98
   PubMed Web of Science ®Google Scholar
• Tosi F, Sartore-Bianchi A, Lonardi S, et al. Long-term Clinical Outcome of Trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer. Clin Colorectal Cancer [Internet]. 2020 [cited 2023 Dec 1];19(4):256–262.e2. doi: 10.1016/j.clcc.2020.06.009
   PubMed Web of Science ®Google Scholar
• Siravegna G, Lazzari L, Crisafulli G, et al. Radiologic and genomic evolution of Individual Metastases during HER2 Blockade in colorectal cancer. Cancer Cell [Internet]. 2018 [cited 2023 Dec 1];34(1):148–162.e7. doi: 10.1016/j.ccell.2018.06.004
   PubMed Web of Science ®Google Scholar
• Strickler JH, Ng K, Cercek A, et al. Mountaineer: open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress). 2021;39:TPS153–TPS153. doi: 10.1200/JCO2021393_supplTPS153
   Google Scholar
• Richard S, Selle F, Lotz JP, et al. Pertuzumab and trastuzumab: the rationale way to synergy. An Acad Bras Cienc [Internet]. 2016 [cited 2023 Dec 1];88(Suppl 1):565–577. Available from: https://pubmed.ncbi.nlm.nih.gov/27275646/
   PubMed Web of Science ®Google Scholar
• Phase-II trial of 5-fluororuacil (5-FU), leucovorin (LV), oxaliplatin (ox), and trastuzamab (T) for patients with metastatic. colorectal cancer (CRC) refractory to initial therapy – ScienceOpen [Internet]. [cited 2023 Dec 1]. Available from: https://www.scienceopen.com/document?vid=2250a47d-e938-4497-a292-6b23e6f5b31b
   Google Scholar
• Ferraro E, Drago JZ, Modi S. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Breast Cancer Res [Internet]. 2021 [cited 2023 Dec 2];23. Available from 1). doi: 10.1186/s13058-021-01459-y
   PubMed Web of Science ®Google Scholar
• Takegawa N, Tsurutani J, Kawakami H, et al. [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification. Int J Cancer [Internet]. 2019 [cited 2023 Dec 2];145(12):3414–3424. doi: 10.1002/ijc.32408
   PubMed Web of Science ®Google Scholar
• Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol [Internet]. 2021 [cited 2023 Dec 3];22(6):779–789. doi: 10.1016/S1470-2045(21)00086-3
   PubMed Web of Science ®Google Scholar
• Raghav KPS, Yoshino T, Guimbaud R, et al. Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02). 2021. p. 39:p. TPS3620–TPS3620. doi: 10.1200/JCO20213915_supplTPS3620
   Google Scholar
• Raghav KPS, Siena S, Takashima A, et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. 2023;41:3501. doi: 10.1200/JCO20234116_suppl3501
   Google Scholar
• Dhimolea E, Reichert JM. World Bispecific Antibody Summit, September 27–28, 2011, Boston, MA. MAbs [Internet]. 2012 [cited 2023 Dec 4];4:4. Available from: /pmc/articles/PMC3338936/
   PubMedGoogle Scholar
• Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med [Internet]. 2018 [cited 2023 Dec 4];378(5):439–448. doi: 10.1056/NEJMoa1709866
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med [Internet]. 2017 [cited 2023 Dec 4];377(26):2531–2544. doi: 10.1056/NEJMoa1707447
   PubMed Web of Science ®Google Scholar
• Munshi NC, Anderson LD, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med [Internet]. 2021 [cited 2023 Dec 4];384(8):705–716. doi: 10.1056/NEJMoa2024850
   PubMed Web of Science ®Google Scholar
• Nathan P, Hassel JC, Rutkowski P, et al. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med [Internet]. 2021 [cited 2023 Dec 4];385(13):1196–1206. doi: 10.1056/NEJMoa2103485
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Nathan P, Sacco JJ, et al. Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. J Clin Oncol [Internet]. 2022 [cited 2023 Dec 4];40(17):1939–1948. doi: 10.1200/JCO.21.01805
   PubMed Web of Science ®Google Scholar
• Syed YY. Amivantamab: First Approval. Drugs [Internet]. 2021 [cited 2023 Dec 4];81:1349–1353. Available from: https://link.springer.com/article/10.1007/s40265-021-01561-7
   Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs [Internet]. 2017 [cited 2023 Dec 4];9(2):182–212. doi: 10.1080/19420862.2016.1268307
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Beeram M, Hamilton E, et al. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol [Internet]. 2022 [cited 2023 Dec 13];23(12):1558–1570. doi: 10.1016/S1470-2045(22)00621-0
   PubMed Web of Science ®Google Scholar
• Shibutani M, Maeda K, Nagahara H, et al. Tumor-infiltrating Lymphocytes Predict the Chemotherapeutic Outcomes in Patients with Stage IV Colorectal Cancer. In Vivo [Internet]. 2018 [cited 2023 Dec 4];32:151–158. Available from: https://pubmed.ncbi.nlm.nih.gov/29275313/
   PubMed Web of Science ®Google Scholar
• Qiao G, Kone LB, Phillips EH, et al. LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer. Oncogene [Internet]. 2022 [cited 2023 Dec 4];41(14):2054–2068. Available from: https://www.nature.com/articles/s41388-022-02209-w
   PubMed Web of Science ®Google Scholar
• Yu P, Lee Y, Liu W, et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol [Internet]. 2004 [cited 2023 Dec 4];5(2):141–149. doi: 10.1038/ni1029
   PubMed Web of Science ®Google Scholar
• Yu P, Fu YX. Targeting tumors with LIGHT to generate metastasis-clearing immunity. Cytokine Growth Factor Rev [Internet]. 2008 [cited 2023 Dec 4];19(3–4):285–294. doi: 10.1016/j.cytogfr.2008.04.004
   PubMed Web of Science ®Google Scholar
• Ross SL, Sherman M, Mcelroy PL, et al. Bispecific T cell engager (BiTE ®) antibody constructs can mediate bystander tumor cell killing. PLOS ONE. 2017 [cited 2023 Dec 4];12(8):e0183390. doi: 10.1371/journal.pone.0183390
   PubMed Web of Science ®Google Scholar
• Boustany LM, LaPorte SL, Wong L, et al. A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity. Cancer Res [Internet]. 2022 [cited 2023 Dec 4];82(22):4288. Available from: /pmc/articles/PMC9664135/
   PubMed Web of Science ®Google Scholar
• Herpers B, Eppink B, James MI, et al. Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors. Nature Cancer [Internet]. 2022 [cited 2023 Dec 13];3(4):418–436. Available from: https://www.nature.com/articles/s43018-022-00359-0
   PubMedGoogle Scholar
• Xu M, Jin H, Chen Z, et al. A novel bispecific diabody targeting both vascular endothelial growth factor receptor 2 and epidermal growth factor receptor for enhanced antitumor activity. Biotechnol Prog [Internet]. 2016 [cited 2023 Dec 4];32(2):294–302. Available from: https://pubmed.ncbi.nlm.nih.gov/26785424/
   PubMed Web of Science ®Google Scholar